Adela develops a blood test platform that detects minimal residual disease (MRD) and monitors treatment response across various cancer types. This technology enables early identification and management of cancer, addressing the critical need for effective monitoring and recurrence prediction in oncology care.
Funding
$111.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting minimal residual disease (MRD) and monitoring treatment response in cancer patients often lack the sensitivity needed for early detection and recurrence prediction. Existing technologies may not be applicable across a wide range of cancer types, limiting their utility in comprehensive oncology care.
Solution
Adela is developing a blood test platform designed to detect MRD and monitor treatment response across various cancer types. The platform aims to provide a scalable solution for early cancer identification and management. By applying a single platform across multiple cancers and applications, Adela seeks to address the unmet need for effective monitoring and recurrence prediction in oncology. The technology is designed to guide the use of adjuvant treatment and monitor for recurrence following surgery, as well as monitor response in patients receiving immunotherapy.
Target Audience
The primary audience includes oncologists and healthcare providers involved in cancer management, as well as patients undergoing cancer treatment and monitoring.
Features
- Blood-based assay for detecting minimal residual disease (MRD)
- Platform applicable across multiple cancer types
- Monitoring of treatment response in immunotherapy patients
- Guidance for adjuvant treatment decisions
- Recurrence monitoring capabilities
- Scalable platform for broad application